Followed 110 TimesTop Followed Top-Rated StocksTop-Rated Most-Upgraded StocksMost-Upgraded

NYSE:LLY

Eli Lilly and Company (LLY) Stock Forecast, Price & News

$537.13

-7.32 (-1.34%)

(As of 09/29/2023 ET)

Compare

Today's Range: $532.20
▼
$546.09
50-Day Range: $449.16
▼
$599.54
52-Week Range: $309.20
▼
$601.84

Volume: 2.97 million shs
Average Volume: 2.75 million shs
Market Capitalization: $509.89 billion

P/E Ratio: 74.71
Dividend Yield: 0.84%
Price Target: $532.78

Eli Lilly and Company MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.86 Rating Score
Upside/Downside: 0.8% Downside
$532.78 Price Target
Short Interest: Healthy
0.74% of Float Sold Short
Dividend Strength: Moderate
Based on Four Factors
Sustainability: -2.25
Upright™ Environmental Score
News Sentiment: 0.71
Based on 22 Articles This Week
Insider Trading: Selling Shares
$20.95 B Sold Last Quarter
Proj. Earnings Growth: 33.23%
From $9.84 to $13.11 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.76 out of 5 stars

Medical Sector

76th out of 972 stocks

Pharmaceutical Preparations Industry

20th out of 449 stocks

2.4

Analyst's Opinion

Consensus Rating
Eli Lilly and Company has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 19 buy ratings, 1 hold rating, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $532.78, Eli Lilly and Company has a forecasted downside of 0.8% from its current price of $537.13.
Amount of Analyst Coverage
Eli Lilly and Company has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
0.74% of the float of Eli Lilly and Company has been sold short.
Short Interest Ratio / Days to Cover
Eli Lilly and Company has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Eli Lilly and Company has recently increased by 11.57%, indicating that investor sentiment is decreasing significantly.

2.5

Dividend Strength

Dividend Yield
Eli Lilly and Company has a dividend yield of 0.84%, which is in the bottom 25% of all stocks that pay dividends.
Dividend Growth
Eli Lilly and Company has been increasing its dividend for 9 years.
Dividend Coverage
The dividend payout ratio of Eli Lilly and Company is 62.87%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Eli Lilly and Company will have a dividend payout ratio of 34.48% next year. This indicates that Eli Lilly and Company will be able to sustain or increase its dividend.

4.0

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Eli Lilly and Company has received a 56.49% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Peptide analogs", "Pemetrexed", "Insulin", and "SGLT2 inhibitors" products. See details.
Environmental Sustainability
The Environmental Impact score for Eli Lilly and Company is -2.25.

2.1

News and Social Media Coverage

News Sentiment
Eli Lilly and Company has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 22 news articles for Eli Lilly and Company this week, compared to 26 articles on an average week.
Search Interest
Only 88 people have searched for LLY on MarketBeat in the last 30 days. This is a decrease of -42% compared to the previous 30 days.
MarketBeat Follows
110 people have added Eli Lilly and Company to their MarketBeat watchlist in the last 30 days. This is an increase of 49% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Eli Lilly and Company insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $20,948,820,977.00 in company stock.
Percentage Held by Insiders
Only 0.13% of the stock of Eli Lilly and Company is held by insiders.
Percentage Held by Institutions
81.38% of the stock of Eli Lilly and Company is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

3.1

Earnings and Valuation

Earnings Growth
Earnings for Eli Lilly and Company are expected to grow by 33.23% in the coming year, from $9.84 to $13.11 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Eli Lilly and Company is 74.71, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 110.88.
Price to Earnings Ratio vs. Sector
The P/E ratio of Eli Lilly and Company is 74.71, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 89.61.
Price to Earnings Growth Ratio
Eli Lilly and Company has a PEG Ratio of 2.21. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Eli Lilly and Company has a P/B Ratio of 47.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Eli Lilly and Company (NYSE:LLY) Stock

Eli Lilly and Company is a US-based multinational pharmaceutical company. It is the 12th largest pharmaceutical company by revenue and has offices in 16 countries. Its medicines are sold in at least 125 countries including its 8 blockbuster drugs. The company is a member of the S&P 500 and S&P 100 indices, it brought in roughly $5.5 billion in revenue for 2021 and employs more than 35,000 people across its network of research and production facilities.

Eli Lilly and Company was founded in 1876 by Colonel Eli Lilly. The colonel, a veteran of the Civil War, had recently dissolved an unsatisfactory partnership and set on his own to produce and develop medicinal chemicals. Colonel Lilly remained as president until his death in 1898. His charge to his family, company and coworkers was to “take what you find here and make it better and better”. The company is well-known for many drugs, including the first mass-marketing of quinine to treat malaria.

The company brought in $4,470 in its first year and saw that figure grow 10X over the next 3. Among the many innovations during this time period is the addition of gelation coatings for pills which helped set the company up for rapid expansion. The company was incorporated in 1881 as Eli Lilly and Company issuing stock to family and friends. The 1900s brought about more change for the company, change in the form of expansion which included international markets.

Advancements during the war years included increases in efficiency due to increased automation and the development of precision technologies. Among the technologies was pill manufacturing which included injecting medicines directly into a gelation capsule. This method allowed for more exact dosing, setting the standard for modern production. The company produced capsules for itself and sold excess capacity to competitors. Other major advancements include fruit flavorings in medicine, straight-line manufacturing and a method of blueprinting manufacturing tickets to prevent errors.

The modern period saw the company grow and discover new, world-class pharmaceuticals. Today, the company is engaged in the discovery, development and marketing of human pharmaceuticals. It offers a wide range of treatments, including Prozac but is perhaps most noteworthy for its work with insulin. The company is the first to mass produce insulin and has made numerous advances in treating diabetes in the time since. While other drugs are more widely known, its diabetic drugs Basaglar, Jardience, Trulicity, Humalog and Humulin are its top-sellers and contribute the bulk of revenue and cash flow.

Along with Diabetic research, the company also focuses on Alzheimer's, Oncology, Immunology, Obesity and Pain care. At the end of 2022, the company pipeline had 23 compounds in Phase 3 clinical trials and 1 in review. There were another 18 in Phase 2 trials and more than 2 dozen in Phase 1 trials. The average cost to discover a new drug was running at $2.6 billion with a 10-year discovery-to-patient timeline.

LLY Price History

30 days | 90 days | 365 days | Advanced Chart

LLY Stock News Headlines

September 20, 2023 | marketbeat.com

Flee to Healthcare Stocks if Recession Rears its Head? (LLY)

In uncertain economic conditions, healthcare stocks can be a refuge due to steady demand and favorable inflation conditions. Many also offer dividends.

September 19, 2023 | marketbeat.com

Could Ely Lilly Be the Best Pharma Stock to Own Now and Forever?

Eli Lilly & Co. stock has been on a tear, trading up 57.7% year-to-date on the strength of its industry-leading medications and highly-anticipated pipeline

October 1, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.

September 18, 2023 | marketbeat.com

Can These 3 Healthcare Dividend Stocks Deliver Income Growth? (LLY)

Healthcare-sector dividend payers Pfizer, Medtronic, and Gilead all boosted shareholder payouts and trade at low multiples relative to potential price gains.

September 1, 2023 | marketbeat.com

How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks? (LLY)

Pharmaceutical stocks are holding steady as Medicare price negotiations approach, but industry diversification and innovation support future growth prospects.

September 30, 2023 | barrons.com

Eli Lilly & Co.

September 29, 2023 | msn.com

Goldman Sachs' Chris Shibutani talks his top biotech picks including Eli Lilly and Pfizer

September 29, 2023 | msn.com

Eli Lilly, Former Employee Settle Lawsuit Concerning Manufacturing Dispute

October 1, 2023 | Stansberry Research (Ad)

Investing Legend Warns: NVIDIA is a "Delusion"

Irrational investment in this tech giant may have made it “too big to succeed” says this renowned expert. Read this before you buy shares.

September 29, 2023 | finance.yahoo.com

3 Stocks to Focus on as Demand for Obesity Drugs Booms

September 29, 2023 | finance.yahoo.com

Upstart Weight-Loss Drugmaker Jumps 75% on Strong Test Results

September 29, 2023 | finance.yahoo.com

Structure Stock Soars. Its Obesity Pill Could Challenge Lilly, Novo.

September 29, 2023 | finance.yahoo.com

Eli Lilly, Silfab Solar among projects helping drive a manufacturing revival in Charlotte region

September 28, 2023 | finance.yahoo.com

Eli Lilly settles whistleblower lawsuit over manufacturing problems

September 28, 2023 | finance.yahoo.com

Lilly Canada to Clean Up Shorelines and Be Citizen Scientists for Global Day of Service

September 28, 2023 | finance.yahoo.com

Global Cancer Pain Market 2023-2028: Eli Lilly & Company and Johnson & Johnson at the Forefront of Personalized Pain Management for Cancer Patients

September 27, 2023 | msn.com

Signal: Eli Lilly’s $176.5m Teva patent infringement loss overturned in US

September 27, 2023 | msn.com

Eli Lilly (LLY) Stock Moves -0.41%: What You Should Know

September 26, 2023 | msn.com

Boehringer and Lilly gain FDA approval for kidney disease therapy

September 26, 2023 | finance.yahoo.com

Wall Street Expects Historic Sales from Ozempic and Other Obesity Treatments

September 26, 2023 | finance.yahoo.com

2 Magnificent Dividend Stocks to Buy Right Now

September 25, 2023 | finance.yahoo.com

FDA Expands Lilly (LLY) Jardiance Label in Chronic Kidney Disease

September 25, 2023 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Eli Lilly & Co (LLY), Centessa Pharmaceuticals (CNTA)

September 22, 2023 | investorplace.com

Immunomics Stocks: 3 Ways to Play This Massive AI-Biotech Megatrend

September 22, 2023 | marketwatch.com

Eli Lilly, Boehringer Ingelheim Get FDA OK for Jardiance in Chronic Kidney Disease

September 22, 2023 | markets.businessinsider.com

Eli Lilly: FDA Approves Jardiance In Treatment Of Chronic Kidney Disease

September 22, 2023 | finance.yahoo.com

Are Wall Street Analysts Wrong About Eli Lilly Stock?

See More Headlines

Receive LLY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eli Lilly and Company and its competitors with MarketBeat's FREE daily newsletter.

LLY Company Calendar

Last Earnings: 8/08/2023
Ex-Dividend for 9/8 Dividend: 8/14/2023
Dividend Payable: 8/15/2023
Dividend Payable: 9/08/2023
Today: 10/01/2023
Next Earnings (Estimated): 11/07/2023
Fiscal Year End: 12/31/2023
Ex-Dividend for 8/15 Dividend: 1/01/2100

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Sector: Medical
Current Symbol: NYSE:LLY
CUSIP: 53245710
CIK: 59478
Web: www.lilly.com
Phone: (317) 276-2000
Fax: 317-276-4878
Employees: 39,000
Year Founded: 1876

Price Target and Rating

Average Stock Price Forecast: $532.78
High Stock Price Forecast: $640.00
Low Stock Price Forecast: $278.00
Forecasted Upside/Downside: -0.8%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.86
Research Coverage: 21 Analysts

Profitability

EPS (Most Recent Fiscal Year): $7.19
Trailing P/E Ratio: 74.71
Forward P/E Ratio: 54.59
P/E Growth: 2.21
Net Income: $6.24 billion
Net Margins: 22.01%
Pretax Margin: 24.67%
Return on Equity: 65.00%
Return on Assets: 13.76%

Debt

Debt-to-Equity Ratio: 1.63
Current Ratio: 1.13
Quick Ratio: 0.87

Sales & Book Value

Annual Sales: $28.54 billion
Price / Sales: 17.87
Cash Flow: $9.17 per share
Price / Cash Flow: 58.60
Book Value: $11.34 per share
Price / Book: 47.37

Miscellaneous

Outstanding Shares: 949,290,000
Free Float: 948,061,000
Market Cap: $509.89 billion
Optionable: Optionable
Beta: 0.32

Social Links

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. David A. Ricks (Age 55)
Chairman, CEO & Pres
Comp: $4.42M

Ms. Anat Ashkenazi (Age 50)
Exec. VP & CFO
Comp: $2.13M

Dr. Daniel M. Skovronsky M.D. (Age 49)
Ph.D., Exec. VP, Chief Scientific & Medical Officer and Pres of Lilly Research Laboratories
Comp: $2.72M

Ms. Anat Hakim J.D. (Age 54)
Exec. VP, Gen. Counsel & Sec.
Comp: $1.98M

Mr. Patrik Jonsson (Age 56)
EVP, Chief Customer Officer, Pres of Lilly USA & Lilly Immunology
Comp: $1.67M

Mr. Donald A. Zakrowski
Chief Accounting Officer & VP of Fin.

Mr. Diogo Rau
EVP & Chief Information and Digital Officer

Mr. Alonzo Weems (Age 52)
EVP of Enterprise Risk Management and Chief Ethics & Compliance Officer

Ms. Leigh Ann Pusey (Age 60)
Exec. VP of Corp. Affairs & Communications

Mr. Eric Dozier (Age 56)
Exec. VP of HR & Diversity

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

LLY Stock - Frequently Asked Questions

Should I buy or sell Eli Lilly and Company stock right now?: 21 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly and Company in the last year. There are currently 1 sell rating, 1 hold rating and 19 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" LLY shares.
View LLY analyst ratings or view top-rated stocks.
What is Eli Lilly and Company's stock price forecast for 2023?: 21 brokers have issued 12-month target prices for Eli Lilly and Company's shares. Their LLY share price forecasts range from $278.00 to $640.00. On average, they expect the company's stock price to reach $532.78 in the next twelve months. This suggests that the stock has a possible downside of 0.8%.
View analysts price targets for LLY or view top-rated stocks among Wall Street analysts.
How have LLY shares performed in 2023?: Eli Lilly and Company's stock was trading at $365.84 on January 1st, 2023. Since then, LLY shares have increased by 46.8% and is now trading at $537.13.
View the best growth stocks for 2023 here.
When is Eli Lilly and Company's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our LLY earnings forecast.
How were Eli Lilly and Company's earnings last quarter?: Eli Lilly and Company (NYSE:LLY) issued its quarterly earnings data on Tuesday, August, 8th. The company reported $2.11 earnings per share for the quarter, beating the consensus estimate of $1.98 by $0.13. The business had revenue of $8.31 billion for the quarter, compared to analyst estimates of $7.58 billion. Eli Lilly and Company had a net margin of 22.01% and a trailing twelve-month return on equity of 65.00%. The company's revenue was up 28.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.25 earnings per share.
Read the conference call transcript.
How often does Eli Lilly and Company pay dividends? What is the dividend yield for Eli Lilly and Company?: Eli Lilly and Company announced a quarterly dividend on Monday, June 26th. Shareholders of record on Tuesday, August 15th will be given a dividend of $1.13 per share on Friday, September 8th. This represents a $4.52 dividend on an annualized basis and a dividend yield of 0.84%. The ex-dividend date of this dividend is Monday, August 14th.
Read our dividend analysis for LLY.
What ETFs hold Eli Lilly and Company's stock?: ETFs with the largest weight of Eli Lilly and Company (NYSE:LLY) stock in their portfolio include iShares U.S. Pharmaceuticals ETF (IHE), Harbor Health Care ETF (MEDI), Invesco S&P 500 Momentum ETF (SPMO), Horizon Kinetics Medical ETF (MEDX), Goldman Sachs Future Health Care Equity ETF (GDOC), iShares U.S. Healthcare ETF (IYH), Health Care Select Sector SPDR Fund (XLV) and Vanguard Health Care ETF (VHT).
Is Eli Lilly and Company a good dividend stock?: Eli Lilly and Company (NYSE:LLY) pays an annual dividend of $4.52 per share and currently has a dividend yield of 0.84%. The company has been increasing its dividend for 9 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio is 62.87%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, LLY will have a dividend payout ratio of 34.48% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for LLY.

What guidance has Eli Lilly and Company issued on next quarter's earnings?: Eli Lilly and Company updated its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share (EPS) guidance of $9.70-$9.90 for the period, compared to the consensus EPS estimate of $8.71. The company issued revenue guidance of $33.40 billion-$33.90 billion, compared to the consensus revenue estimate of $31.44 billion.
What is David A. Ricks' approval rating as Eli Lilly and Company's CEO?: 399 employees have rated Eli Lilly and Company Chief Executive Officer David A. Ricks on Glassdoor.com. David A. Ricks has an approval rating of 86% among the company's employees.
What other stocks do shareholders of Eli Lilly and Company own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Eli Lilly and Company investors own include Johnson & Johnson (JNJ), Pfizer (PFE), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Bristol-Myers Squibb (BMY), Walt Disney (DIS), AT&T (T), Verizon Communications (VZ) and JPMorgan Chase & Co. (JPM).
What is Eli Lilly and Company's stock symbol?: Eli Lilly and Company trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."
How do I buy shares of Eli Lilly and Company?: Shares of LLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Eli Lilly and Company's stock price today?: One share of LLY stock can currently be purchased for approximately $537.13.
How much money does Eli Lilly and Company make?: Eli Lilly and Company (NYSE:LLY) has a market capitalization of $509.89 billion and generates $28.54 billion in revenue each year. The company earns $6.24 billion in net income (profit) each year or $7.19 on an earnings per share basis.
How many employees does Eli Lilly and Company have?: The company employs 39,000 workers across the globe.
Does Eli Lilly and Company have any subsidiaries?: The following companies are subsidiares of Eli Lilly and Company: 1096401 B.C. Unlimited Liability Company, ARMO Biosciences Inc., Acanthas Pharma Inc., Advanced Cardiovascular Systems, Alnara Pharmaceuticals, Alnara Pharmaceuticals Inc., Andean Technical Operations Center, Applied Molecular Evolution Inc., AurKa Pharma Inc., Avid Radiopharmaceuticals, Avid Radiopharmaceuticals Inc., ChemGen, CoLucid Pharmaceuticals, CoLucid Pharmaceuticals Inc., Compania Farmaceutica Eli Lilly de Centro America S.A., Dermira, Dermira Canada, Dermira Inc., Devices for Vascular Intervention(DVI), Disarm Therapeutics, Disarm Therapeutics, Disarm Therapeutics Inc., Dista Ilac Ticaret Ltd. Sti., Dista S.A., Dista-Produtos Quimicos & Farmaceuticos LDA, ELCO Dominicana SRL, ELCO Insurance Company Limited, ELCO Management Inc., ELCO for Trade and Marketing S.A.E., ELGO Insurance Company Limited, Elanco Animal Health Ireland Limited, Elanco Switzerland Holding Sarl, Eli Lilly (Malaysia) Sdn. Bhd., Eli Lilly (Philippines) Incorporated, Eli Lilly (S.A.) (Proprietary) Limited, Eli Lilly (Singapore) Pte. Ltd., Eli Lilly (Suisse) S.A., Eli Lilly Asia Inc., Eli Lilly Asia Pacific SSC Sdn Bhd, Eli Lilly Australia Pty. Limited, Eli Lilly B-H d.o.o., Eli Lilly Benelux S.A., Eli Lilly Bienes y Servicios S de RL de CV, Eli Lilly CR s.r.o., Eli Lilly Canada Inc., Eli Lilly Cork Limited, Eli Lilly Danmark A/S, Eli Lilly Egypt for Trading, Eli Lilly European Clinical Trial Services SA, Eli Lilly Export S.A., Eli Lilly Finance S.A., Eli Lilly Ges.m.b.H., Eli Lilly Group Limited, Eli Lilly Holdings Ltd., Eli Lilly Hrvatska d.o.o., Eli Lilly Interamerica Inc., Eli Lilly Interamerica Inc. y Compania Limitada, Eli Lilly International Corporation, Eli Lilly Ireland Holdings Limited, Eli Lilly Israel Ltd., Eli Lilly Italia S.p.A., Eli Lilly Japan K.K., Eli Lilly Kinsale Limited, Eli Lilly Nederland B.V., Eli Lilly Nigeria Ltd., Eli Lilly Norge A.S., Eli Lilly Pakistan (Pvt.) Ltd., Eli Lilly Polska Sp.z.o.o. (Ltd.), Eli Lilly Regional Operations GmbH, Eli Lilly Romania SRL, Eli Lilly S.A., Eli Lilly Saudi Arabia Limited, Eli Lilly Services India Private Limited, Eli Lilly Slovakia s.r.o., Eli Lilly Sweden AB, Eli Lilly Vostok S.A. Geneva, Eli Lilly and Company, Eli Lilly and Company (India) Pvt. Ltd., Eli Lilly and Company (Ireland) Limited, Eli Lilly and Company (N.Z.) Limited, Eli Lilly and Company (Taiwan) Inc., Eli Lilly and Company Limited, Eli Lilly do Brasil Limitada, Eli Lilly farmacevtska druzba d.o.o., Eli Lilly y Compania de Mexico S.A. de C.V., Eli Lilly y Compania de Venezuela S.A., Glycostasis Inc., Greenfield-Produtos Farmaceuticos Lda., Heart Rhythm Technologies Inc, Hybritech, Hypnion, ICOS Corporation, ICOS Corporation, ImClone GmbH, ImClone LLC, ImClone Systems Holdings Inc., ImClone Systems LLC, Imclone Systems, Irisfarma S.A., Ivy Animal Health, LDH I Corporation, Lilly (Shanghai) Management Co. Ltd., Lilly Asia Ventures Fund I L.P., Lilly Asia Ventures Fund II L.P., Lilly Asian Ventures Fund III L.P., Lilly Cayman Holdings, Lilly Centre for Clinical Pharmacology PTE. LTD., Lilly China Research and Development Co. Ltd, Lilly Deutschland GmbH, Lilly France S.A.S., Lilly Global Nederland Holdings B.V., Lilly Global Services Inc., Lilly Holding GmbH, Lilly Holdings B.V., Lilly Hungaria KFT, Lilly Japan Financing G.K., Lilly Korea Ltd., Lilly Nederland Finance B.V., Lilly Nederland Finance B.V. - GCC, Lilly Nederland Holding B.V., Lilly Pharma Ltd., Lilly Portugal - Produtos Farmaceuticos Lda., Lilly S.A., Lilly Suzhou Pharmaceutical Co. Ltd., Lilly Trading Co. LTD, Lilly USA LLC, Lilly Ventures Fund I LLC, Lilly del Caribe Inc., Lilly ilaç ticaret limited şirketi, Lohmann Animal Health, Loxo Oncology, Loxo Oncology Inc., Novartis Animal Health, OY Eli Lilly Finland AB, Origin Medsystems, PT. Eli Lilly Indonesia, Pacific Biotech, Petra Pharma Corporation, Pharmaserve-Lilly S.A.C.I., Pharmaserve-Lilly S.A.C.I., Physio-Control, Prevail Therapeutics Inc., Protomer Technologies, SGX Pharmaceuticals, SGX Pharmaceuticals Inc., Spaly Bioquimica S.A., UAB Eli Lilly Lietuva, Valquifarma S.A., and Vital Pharma Productos Farmaceuticos.
Read More
How can I contact Eli Lilly and Company?: Eli Lilly and Company's mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The official website for the company is www.lilly.com. The company can be reached via phone at (317) 276-2000, via email at johnson_philip_l@lilly.com, or via fax at 317-276-4878.

This page (NYSE:LLY) was last updated on 10/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Eli Lilly and Company (LLY) Stock Forecast, Price & News

Eli Lilly and Company MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Eli Lilly and Company (NYSE:LLY) Stock

LLY Price History

LLY Stock News Headlines

LLY Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

LLY Stock - Frequently Asked Questions

Overall MarketRank^™